ReviewCureus2024
Emerging Trends in Atherosclerosis: Time to Address Atherosclerosis From a Younger Age.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Empagliflozin Improves Atherosclerosis by Promoting Mitophagy in Endothelial Cells.Cardiovascular drugs and therapy · 2026Article
- Distinct From the Adult Paradigm: Re-Evaluate the Pathophysiological and Therapeutic Framework in Children and Adolescent Hyperlipidaemia.Current obesity reports · 2026Review
- Deployable 3D-Printed Vascular Stent with Surface-Catalysed Endogenous Nitric Oxide Generation.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Article
- Review
- Glucocorticoid receptor epigenetic activity in the heart.Epigenetics · 2025Review
- Retinal Microvascular Profile of Patients with Coronary Artery Disease.Medicina (Kaunas, Lithuania) · 2025Article
- Association between serum retinol-binding protein and lower limb atherosclerosis risk in type 2 diabetes mellitus.World journal of diabetes · 2025Article
- Article
- Associations of novel blood-derived markers of inflammation with blood pressure, arterial stiffness and heart rate in young adults.Frontiers in cardiovascular medicine · 2025Article
- Article
- Statin Use in Children and Adolescents - Dos, Don'ts and Practical Tips.Current atherosclerosis reports · 2024Review
- Discovering Inflammation in Atherosclerosis: Insights from Pathogenic Pathways to Clinical Practice.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past two decades, research efforts into cardiovascular disease (CVD) have uncovered findings that fundamentally challenge our understanding of CVD, particularly atherosclerosis. Atherosclerosis was primarily attributed to the well-described abnormal lipid accumulation theory, involving plaque growth with subsequent plaque hemorrhage resulting in acute vessel thrombosis that may or may not rupture. This perspective has now evolved to encompass more complex pathways, wherein the accumulation of abnormal products of oxidation and inflammation is the most likely factor mediating atherosclerotic plaque growth. Furthermore, atherosclerosis was traditionally thought of as a disease in patients aged 40 and older. However, mounting evidence has demonstrated that significant atherosclerosis and CVD events are more prevalent in younger patients than previously realized and accelerating in incidence. With this alarming trend among younger individuals, our review sought to explore why this trend may be happening and what can be done about this developing problem.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.